S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
NASDAQ:CYCN

Cyclerion Therapeutics News Headlines

$2.44
-0.01 (-0.41%)
(As of 11/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.30
$2.50
50-Day Range
$2.17
$3.49
52-Week Range
$2.08
$6.90
Volume
402,662 shs
Average Volume
788,799 shs
Market Capitalization
$105.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.69

Media Mentions By Week



Cyclerion Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CYCN
News Sentiment

0.33

0.27

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CYCN Articles
This Week

6

0

CYCN Articles
Average Week

Get Cyclerion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.

Cyclerion Therapeutics (NASDAQ:CYCN) News Headlines Today

SourceHeadline
finance.yahoo.com logoCyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their holding by 67% earlier this year
finance.yahoo.com - November 25 at 8:22 AM
MarketBeat logoCantor Fitzgerald Comments on Cyclerion Therapeutics, Inc.'s FY2021 Earnings (NASDAQ:CYCN)
americanbankingnews.com - November 25 at 7:20 AM
MarketBeat logoCyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update
americanbankingnews.com - November 22 at 3:18 AM
MarketBeat logoCyclerion Therapeutics (NASDAQ:CYCN) Releases Quarterly Earnings Results
americanbankingnews.com - November 10 at 12:46 PM
finance.yahoo.com logoCyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
finance.yahoo.com - November 9 at 5:59 PM
finance.yahoo.com logoTruist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside
finance.yahoo.com - October 20 at 8:19 PM
fool.com logoCyclerion Therapeutics Inc(CYCN)
fool.com - September 17 at 12:44 AM
finance.yahoo.com logoCyclerion Therapeutics to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - September 8 at 8:38 AM
msn.com logoWhy Cyclerion Therapeutics Shares Are Moving Today
msn.com - July 23 at 12:51 PM
finance.yahoo.com logoCyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Are Down 31% On Their Shares
finance.yahoo.com - July 12 at 8:28 AM
finance.yahoo.com logoCyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers
finance.yahoo.com - July 9 at 9:54 AM
finance.yahoo.com logoCyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
finance.yahoo.com - July 8 at 6:29 PM
nasdaq.com logoTuesday 6/8 Insider Buying Report: WSC, CYCN
nasdaq.com - June 8 at 1:04 PM
nasdaq.com logoCyclerion Reaches Licensing Agreement With Akebia For Oral SGC Stimulator Praliciguat
nasdaq.com - June 4 at 12:29 PM
finance.yahoo.com logoCyclerion Therapeutics Announces $18 Million Private Placement
finance.yahoo.com - June 4 at 12:29 PM
finance.yahoo.com logoCyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
finance.yahoo.com - June 4 at 12:29 PM
finance.yahoo.com logoCyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
finance.yahoo.com - May 27 at 6:36 PM
finance.yahoo.com logoCyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 25 at 10:16 AM
finance.yahoo.com logoThe CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More Shares
finance.yahoo.com - May 9 at 1:26 PM
nasdaq.com logoFriday 5/7 Insider Buying Report: CYCN, WY
nasdaq.com - May 7 at 1:38 PM
nasdaq.com logoStock Alert: Cyclerion Therapeutics Jumps 13% As CEO Raises Stake In Co.
nasdaq.com - May 7 at 1:38 PM
uk.finance.yahoo.com logoCyclerion Therapeutics Inc (CYCN) CEO Peter M Hecht Bought $1.7 million of Shares
uk.finance.yahoo.com - May 7 at 8:36 AM
finance.yahoo.com logoCyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress
finance.yahoo.com - April 27 at 1:41 PM
finance.yahoo.com logoCyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
finance.yahoo.com - April 26 at 8:22 AM
finance.yahoo.com logoCyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
finance.yahoo.com - April 21 at 9:38 AM
finance.yahoo.com logoCyclerion Therapeutics to Host Pipeline Update Webinar
finance.yahoo.com - April 20 at 8:41 AM
finance.yahoo.com logoAre Institutions Heavily Invested In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?
finance.yahoo.com - March 22 at 8:57 AM
finance.yahoo.com logoCyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
finance.yahoo.com - February 25 at 8:14 AM
finance.yahoo.com logoCyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
finance.yahoo.com - January 25 at 8:38 AM
finance.yahoo.com logoHow Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year?
finance.yahoo.com - January 21 at 10:30 AM
finance.yahoo.com logoCyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
finance.yahoo.com - January 4 at 7:30 AM
finance.yahoo.com logoCyclerion Announces Leadership Transitions
finance.yahoo.com - December 21 at 12:23 PM
finance.yahoo.com logoCyclerion Therapeutics, Inc. (CYCN)
finance.yahoo.com - December 6 at 9:38 PM
finance.yahoo.com logoIs Cyclerion Therapeutics, Inc. (CYCN) A Good Stock To Buy?
finance.yahoo.com - December 2 at 11:34 PM
nasdaq.com logoChief Innovation Officer Andreas Busch Just Bought 96% More Shares In Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)
nasdaq.com - November 15 at 8:50 AM
finance.yahoo.com logoAndreas Busch Is The Chief Innovation Officer of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) And They Just Picked Up 96% More Shares
finance.yahoo.com - November 15 at 8:50 AM
nasdaq.com logoFriday 11/13 Insider Buying Report: CYCN
nasdaq.com - November 13 at 12:48 PM
finance.yahoo.com logoCyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
finance.yahoo.com - November 5 at 12:03 PM
finance.yahoo.com logoWhy Cyclerion Therapeutics Is Crashing Today
finance.yahoo.com - October 22 at 4:22 PM
benzinga.com logoMid-Day Market Update: Crude Oil Rises 1.5%; Cyclerion Therapeutics Shares Plummet
benzinga.com - October 14 at 6:10 PM
seekingalpha.com logoCyclerion shows encouraging action in early-stage study
seekingalpha.com - October 14 at 6:10 PM
msn.com logoCyclerion Sinks As Biopharma Shelves Sickle Cell Disease Study
msn.com - October 14 at 6:10 PM
seekingalpha.com logoCyclerion shows encouraging action in early-stage study in elderly volunteers
seekingalpha.com - October 14 at 1:10 PM
seekingalpha.com logoCyclerion's olinciguat data in sickle cell did not support clinical development
seekingalpha.com - October 14 at 1:10 PM
markets.businessinsider.com logoCyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects
markets.businessinsider.com - October 14 at 8:08 AM
markets.businessinsider.com logoCyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease
markets.businessinsider.com - October 14 at 8:08 AM
seekingalpha.com logoCyclerion's shows encouraging action in early-stage study
seekingalpha.com - October 14 at 8:08 AM
seekingalpha.com logoCyclerion Is A Speculative Biotech With A Few Catalysts Approaching
seekingalpha.com - October 13 at 7:09 AM
nasdaq.com logoWeek Ahead In Pharma: Clinical Trial Readouts, FDA Decision (ETON, SELB, CRBP…)
nasdaq.com - September 27 at 7:17 AM
seekingalpha.com logoCyclerion Therapeutics inks $50M stock sales deal with Jefferies
seekingalpha.com - September 3 at 9:57 AM
Get Cyclerion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.